Rizatriptan oral film - IntelGenx/RedHill Biopharma

Drug Profile

Rizatriptan oral film - IntelGenx/RedHill Biopharma

Alternative Names: INT 0008/2007; INT0008; RHB-103; Rizaport; Rizatriptan benzoate oral thin film - IntelGenx/RedHill Biopharma

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IntelGenx Corp.
  • Developer Grupo Juste; IntelGenx Corp.; RedHill Biopharma
  • Class Antimigraines; Small molecules; Triazoles; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Migraine

Highest Development Phases

  • Registered Migraine

Most Recent Events

  • 13 Apr 2017 Registered for Migraine in Luxembourg - Decentralised procedure (PO)
  • 14 Dec 2016 RedHill BioPharma and IntelGenx enter into a registration and commercialisation agreement with Pharmatronic for rizatriptan oral film in South Korea
  • 14 Dec 2016 Preregistration for Migraine in Spain (PO) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top